Q² Solutions (IQVIA) Acquires Nexelis from Ampersand Capital Partners
January 10, 2022
Ampersand Capital Partners sold its portfolio company Nexelis to Q² Solutions, a wholly owned subsidiary of IQVIA, Inc. Nexelis, a Laval, Quebec–based provider of assay development and advanced clinical-trial laboratory testing with five operating sites in North America and Europe, will be integrated into IQVIA's global laboratory services to expand capabilities and capacity for vaccine, immunology and other drug-development testing.
- Buyers
- Q² Solutions (a wholly owned subsidiary of IQVIA, Inc.)
- Targets
- Nexelis
- Sellers
- Ampersand Capital Partners
- Industry
- Healthcare Services
- Location
- Quebec, Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Nexelis to Acquire ImmunXperts
April 4, 2020
Healthcare Services
Nexelis, a portfolio company of Ampersand Capital Partners, has signed a definitive agreement to acquire ImmunXperts, a specialty immunogenicity and immuno‑oncology testing laboratory based in Gosselies, Belgium. The add-on deal will expand Nexelis' assay development and immunology testing capabilities and is expected to close by the end of March 2020.
-
Nexelis Acquires AIT Bioscience
July 22, 2020
Healthcare Services
Nexelis, a portfolio company of Ampersand Capital Partners, has acquired AIT Bioscience, an Indianapolis-based integrated bioanalytical CRO with LC‑MS and immunoassay testing capabilities. The add-on expands Nexelis' bioanalytical services (including large-molecule mass spectrometry) and establishes operations in Indianapolis to support future growth and faster turnaround times.
-
Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory (Marburg)
January 20, 2021
Biotechnology
Nexelis, a portfolio company of Ampersand Capital Partners, has signed an asset purchase agreement to acquire GSK's GCLP-certified clinical bioanalytical laboratory in Marburg, Germany. Approximately 80 scientists and analysts will transfer to Nexelis, which also entered a five-year strategic collaboration with GSK to continue supporting vaccine development while expanding Nexelis' assay development and high-throughput clinical testing capabilities in Europe.
-
PerkinElmer Acquires Nexcelom Bioscience for $260M
May 13, 2021
Medical Devices
PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.
-
Catabasis Pharmaceuticals Acquires Quellis Biosciences Inc.
January 29, 2021
Biotechnology
Catabasis Pharmaceuticals has acquired Quellis Biosciences in a stock-for-stock merger to obtain Quellis' lead preclinical monoclonal antibody program QLS-215 for hereditary angioedema. Concurrent with the acquisition, Catabasis completed a private placement (PIPE) led by Perceptive Advisors and other institutional investors to raise approximately $110 million to fund IND-enabling studies and early clinical trials of QLS-215.
-
ELIQUENT Life Sciences Acquires Azzur Consulting
May 7, 2025
Healthcare Services
ELIQUENT Life Sciences, a GHO Capital‑backed global regulatory, quality, and safety consulting firm, has acquired Azzur Consulting to strengthen its validation engineering, CQV, and quality/compliance capabilities. The Azzur team will integrate into ELIQUENT's global delivery organization to expand technical delivery across North America, Europe, Japan and other markets.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.